Dexotix60 mg+1200 mg

Dexotix is a fixed-dose combination of an antitussive (cough suppressant) and an expectorant, marketed as an over-the-counter (OTC) product under the FDA Cough-Cold Monograph.

Established / OTC-Monograph Uses

• Temporary relief of cough due to minor throat and bronchial irritation associated with the common cold or inhaled irritants.
• Helps loosen phlegm (mucus) and thin bronchial secretions, making coughs more productive, in the setting of the common cold or minor upper respiratory tract infections.

Not Indicated For

Dexotix does not treat the underlying cause of cough or chest congestion and is not a substitute for medical evaluation. It is not intended for chronic cough associated with smoking, emphysema, or chronic bronchitis, for cough with excessive secretions, or for cough lasting longer than 7 days, unless directed by a physician.

Dextromethorphan Hydrobromide + Guaifenesin combines two active ingredients in a single dosage form:

• Dextromethorphan Hydrobromide - a centrally-acting antitussive.
• Guaifenesin - an expectorant.

Strength ratios vary by brand and dosage form (e.g., syrups commonly providing Dextromethorphan Hydrobromide 10-15 mg with Guaifenesin 100-200 mg per 5 mL; extended-release tablets commonly providing Dextromethorphan Hydrobromide 30 mg with Guaifenesin 1200 mg per tablet). Always check the specific product label of Dextromethorphan Hydrobromide + Guaifenesin for the exact strength dispensed.

Dexotix is a combination over-the-counter cold and cough preparation. Dextromethorphan Hydrobromide suppresses the cough reflex by acting on the cough center in the brainstem, while Guaifenesin acts as an expectorant that helps thin and loosen mucus in the airways, making it easier to clear by coughing.

Dexotix is available in several dosage forms, including immediate-release syrups/liquids, immediate-release tablets or capsules, and extended-release tablets, and is intended for short-term, symptomatic relief of cough and chest congestion associated with the common cold.

Antitussive (Cough Suppressant) and Expectorant Combination - OTC Cold and Cough Preparation (Dexotix)

Dextromethorphan Hydrobromide + Guaifenesin combines two agents with complementary mechanisms for symptomatic cough and congestion relief.

Dextromethorphan Hydrobromide

Dextromethorphan is a centrally-acting antitussive that raises the threshold for coughing by acting on the cough center in the medulla, primarily through antagonism of NMDA glutamate receptors and agonism at sigma-1 receptors, without significant analgesic or dependence-producing activity at labeled doses.

Guaifenesin

Guaifenesin is an expectorant thought to act by increasing the volume and reducing the viscosity of respiratory tract secretions through a reflex mechanism (gastric mucosal irritation stimulating vagal afferents), which facilitates expectoration of retained mucus.

Together, the components of Dextromethorphan Hydrobromide + Guaifenesin provide symptomatic relief of a dry, non-productive cough while helping to loosen chest congestion.

Dexotix is taken by mouth.

• For liquid formulations, use the dosing cup, syringe, or spoon provided with the product; do not use an ordinary household spoon, as this can lead to inaccurate dosing.
• Extended-release tablets must be swallowed whole with water; do not crush, chew, or split them.
• Dexotix may be taken with or without food; taking with food may reduce mild stomach upset.
• Space doses at least 4 hours apart for immediate-release products (or 12 hours for extended-release products), and do not exceed the maximum number of doses in 24 hours stated on the label.
• Drink adequate fluids while taking Dexotix, as this supports the mucus-thinning action of guaifenesin.

Clinically significant interactions with Dexotix relate mainly to its dextromethorphan component:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, can precipitate serious, potentially fatal serotonin syndrome and is contraindicated (see Contraindications).
• Serotonergic drugs (e.g., SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol, linezolid): Concurrent use with Dexotix increases the risk of serotonin syndrome; use with caution and monitor for symptoms such as agitation, tremor, hyperthermia, and altered mental status.
• Strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine, bupropion, terbinafine): May increase dextromethorphan blood levels and the risk of CNS and serotonergic adverse effects.
• Alcohol and other CNS depressants (sedatives, opioids): Additive drowsiness/CNS depression may occur.
• Other cough, cold, or allergy products: Avoid concurrent use of other products containing dextromethorphan or guaifenesin, or other antitussives/expectorants, to prevent inadvertent overdose.

Most people tolerate Dexotix well when used as labeled. Reported side effects include:

• Common: Mild drowsiness or dizziness, nausea, vomiting, stomach upset, headache.
• Less common: Skin rash or allergic reaction.
• Rare / with misuse or high doses: Confusion, hallucinations, dissociative effects, restlessness, and symptoms of serotonin syndrome (agitation, rapid heartbeat, high fever, muscle rigidity) - see Precautions and Overdose.

Seek medical attention if a rash, difficulty breathing, swelling, or severe dizziness occurs after taking Dexotix.

Pregnancy: Data on the use of Dexotix in human pregnancy are limited. As with most OTC cough/cold products, Dexotix should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not well established whether the components of Dexotix pass into breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before using Dexotix while breastfeeding, particularly monitoring the infant for unusual drowsiness or irritability.

• See a doctor before use if cough is accompanied by high fever, rash, persistent headache, or if cough persists for more than 7 days, tends to recur, or is accompanied by excessive phlegm, as these may indicate a condition requiring medical evaluation.
• Misuse/abuse potential: Dextromethorphan, a component of Dexotix, has recognized potential for misuse at doses well above the labeled dose, producing dissociative or hallucinogenic effects ("robotripping"). Use only at the labeled dose, and be alert to this risk particularly when dispensing to adolescents and young adults.
• Serotonin syndrome: Risk increases with concurrent MAOIs (contraindicated) or other serotonergic medications (see Interactions).
• Do not combine with other OTC cough, cold, or allergy products, as this can lead to duplicate ingredient overdose.
• Drowsiness is usually mild but caution is reasonable when driving or operating machinery until individual response to Dexotix is known.
• Maintain adequate fluid intake, which supports the expectorant action of guaifenesin.
• Keep Dexotix out of reach of children; accidental ingestion can be serious.

Overdose of Dexotix may cause excessive drowsiness, dizziness, blurred vision, nausea, vomiting, ataxia (unsteady movement), nystagmus, rapid heartbeat, agitation, hallucinations, and, in severe cases, respiratory depression, seizures, or serotonin syndrome (especially if combined with serotonergic drugs).

If an overdose of Dexotix is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt specific home treatment; supportive care in a medical facility may be required.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal/hepatic impairment: Well-controlled studies are lacking; use Dexotix with caution and consult a physician, as clearance of the components may be reduced.
• Elderly: May be more sensitive to the CNS effects (drowsiness, dizziness) of Dexotix; start with caution and monitor for adverse effects.
• Children: Use only age-appropriate labeled products and doses (see Dosage and Pediatric Uses); Dexotix is generally not recommended for children under 4 years of age unless specifically directed by a physician.
• Pregnant or breastfeeding individuals: See Pregnancy and Lactation.

Dexotix is intended for short-term, symptomatic use only, typically for up to 7 days. If cough or congestion has not improved, worsens, or is accompanied by fever, rash, or persistent headache after 7 days of using Dexotix, discontinue use and consult a physician, as a different underlying condition may need to be addressed.

Antitussive (NMDA-receptor antagonist / sigma-1 receptor agonist) combined with an Expectorant (Dextromethorphan Hydrobromide + Guaifenesin)

Dextromethorphan Hydrobromide + Guaifenesin acts through two complementary mechanisms:

• Dextromethorphan Hydrobromide suppresses the cough reflex centrally by elevating the cough threshold at the medullary cough center, mediated through NMDA-receptor antagonism and sigma-1 receptor agonism.
• Guaifenesin increases the output and reduces the viscosity of respiratory secretions via a vagally-mediated reflex triggered by mild gastric mucosal irritation, thereby facilitating expectoration.

C

Pediatric dosing of Dexotix is age- and weight-based and depends on the specific product; always use a formulation specifically labeled for the child's age.

• Children 12 years and older: Adult dosing as labeled.
• Children 6-11 years: Half the adult dose, as labeled.
• Children 4-5 years: Use only if a specific product is labeled for this age group, or as directed by a physician.
• Children under 4 years: Safety and efficacy of Dexotix have not been established in this age group; current OTC cough/cold labeling guidance recommends against use unless specifically directed by a physician.

Parents/caregivers should be counseled on accurate dosing using the device provided with the product and on the misuse potential of dextromethorphan in older children and adolescents.